Compare ED & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ED | VCEL |
|---|---|---|
| Founded | 1884 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | ED | VCEL |
|---|---|---|
| Price | $100.15 | $40.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $104.54 | $57.50 |
| AVG Volume (30 Days) | ★ 1.8M | 592.2K |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | 7.94 | ★ 236.54 |
| EPS | ★ 5.74 | 0.25 |
| Revenue | ★ $16,593,000,000.00 | $258,716,999.00 |
| Revenue This Year | $11.45 | $17.86 |
| Revenue Next Year | $3.35 | $18.55 |
| P/E Ratio | ★ $17.32 | $163.62 |
| Revenue Growth | 10.39 | ★ 14.05 |
| 52 Week Low | $87.28 | $29.24 |
| 52 Week High | $114.87 | $63.00 |
| Indicator | ED | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 65.33 |
| Support Level | $96.96 | $35.33 |
| Resistance Level | $100.60 | $38.15 |
| Average True Range (ATR) | 1.38 | 1.46 |
| MACD | 0.10 | 0.45 |
| Stochastic Oscillator | 71.23 | 88.69 |
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.